Evidence map›Paper›PMID 28971965›Full record

ArticleClinical and vaccine immunology : CVI2017

Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Darren Abbanat, Todd A Davies, Karen Amsler, Wenping He, Kellen Fae, Sarah Janssen, Jan T Poolman, Germie P J M van den Dobbelsteen

Open access · diamondAbstract readEvaluation Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Darren AbbanatJanssen Research & Development, Raritan, New Jersey, USA dabbanat@its.jnj.com.
Todd A DaviesJanssen Research & Development, Raritan, New Jersey, USA.
Karen AmslerJanssen Research & Development, Raritan, New Jersey, USA.
Wenping HeJanssen Research & Development, Raritan, New Jersey, USA.
Kellen FaeJanssen Vaccines & Prevention B.V., Bacterial Vaccines Discovery & Early Development, Leiden, The Netherlands.
Sarah JanssenJanssen Vaccines & Prevention B.V., Statistics & Decision Sciences, Leiden, The Netherlands.
Jan T PoolmanJanssen Vaccines & Prevention B.V., Bacterial Vaccines Discovery & Early Development, Leiden, The Netherlands.
Germie P J M van den DobbelsteenJanssen Vaccines & Prevention B.V., Bacterial Vaccines Discovery & Early Development, Leiden, The Netherlands.
Janssen (Netherlands) · NLJanssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global burden of disease caused by extraintestinal pathogenic

Indexed as

PhagocytosisEscherichia coli VaccinesHumansImmunoassayOpsonin ProteinsSensitivity and SpecificityEscherichia coli VaccinesOpsonin Proteinsassay qualificationbacteremiaconjugate vaccineEscherichia coliExPECinvasive diseaseopsonophagocytic killing assay

Identifiers

PMID28971965
PMCPMC5717180
OpenAlexW2758504765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.